Stock 603998 HUNAN FANGSHENG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Hunan Fangsheng Pharmaceutical Co., Ltd.

Equities

603998

CNE100001VG6

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 31/05/2024 am IST 		5-day change 1st Jan Change
11.84 CNY +0.17% Intraday chart for Hunan Fangsheng Pharmaceutical Co., Ltd. -0.84% +8.03%
19/04 Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
10/04 Fangsheng Pharma's Factories Pass GMP Inspection MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Fangsheng Pharma's Factories Pass GMP Inspection
MT
Fangsheng Pharma Gets 12.1 Million Yuan in Government Grants in January-March
MT
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Hunan Fangsheng Pharmaceutical Sees Up to 357% Surge in 2022 Profit; Shares Jump 3%
MT
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Guo Jianjun agree to acquire 50% stake in Hunan Hengxing Pharmaceutical Technology Co., Ltd. from Hunan Fangsheng Pharmaceutical Co., Ltd. for CNY 9.4 million.
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. agreed to acquire Jiangxi Tengwangge Pharmaceutical Co., Ltd from Hunan Fangsheng Pharmaceutical Co., Ltd., Hunan Yuanhuixuan Management Consulting Co., Ltd and Guangzhou Changyixing Investment Management Co., Ltd for CNY
CI
He Ye entered into share transfer agreement to acquire 51% stake in Yingkou Sanhua Pharmaceutical Co., Ltd. from Hunan Fangsheng Pharmaceutical Co., Ltd. for CNY 24 million
CI
Davita's China Affiliate to Invest in Hunan Fangsheng Pharma's Unit for 31.7% Stake
CI
Hunan Baijun Hi-Tech Medical Investment Management Co., Ltd. ESOP and Davita China Pte. Ltd. agreed to acquire 41.7% stake in Hunan Baijun Hi-Tech Medical Investment Management Co., Ltd. from Changsha Kanglai Health Management Co., Ltd. and Hunan Fangsheng Pharmaceutical Co., Ltd..
CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
China blue-chip shares end higher on healthcare, banking gains
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603998 Stock
  4. News Hunan Fangsheng Pharmaceutical Co., Ltd.
  5. Highlights